<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35039">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765920</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-ER-006</org_study_id>
    <nct_id>NCT01765920</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients</brief_title>
  <official_title>Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to assess safety of the liquid dosage form of Ergoferon for treatment of acute upper
           respiratory tract infections in adult patients.

        -  to assess clinical efficiency of the liquid dosage form of Ergoferon for treatment of
           acute upper respiratory tract infections in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Average duration of fever (body temperature over 37.0 С) (according to the patient's diary).</measure>
    <time_frame>7(± 1) days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamics of the clinical manifestations of ARI according to the objective medical examination (summary score of the CCQ scale at first, third and seventh days of treatment)</measure>
    <time_frame>7(± 1) days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Acute Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Ergoferon (5 ml 3 times a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (5 ml 3 times a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergoferon</intervention_name>
    <description>Safety and Efficiency of liquid dosage form</description>
    <arm_group_label>Ergoferon (5 ml 3 times a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficiency of liquid dosage form</description>
    <arm_group_label>Placebo (5 ml 3 times a day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged from 18 to 60 inclusively.

          2. Patients who consulted a doctor during the increase of seasonal incidence within 24
             hours after the onset of acute upper respiratory tract infection.

          3. Body temperature at least 37.8 °С at the moment of examination by the doctor.

          4. Presence of two or more moderate level symptoms or three or more mild level symptoms
             according to the CCQ scale.

          5. The possibility to start therapy within 24 hours after the onset of the first
             symptoms of acute upper respiratory tract infection.

          6. Usage of contraceptive methods by the patients of both the sexes during the trial and
             within 30 days after ending of the participation in the trial.

          7. Availability of information sheet (informed consent form for taking part in the
             clinical trial) signed by the patient.

        Exclusion Criteria:

          1. Suspected invasive bacterial infection or presence of severe disease requiring use of
             antibacterial drugs (including sulfanilamides).

          2. Suspected initial manifestations of diseases that have symptoms similar to ARI (other
             infectious diseases, flu-like symptoms at the onset of systemic connective tissue
             disorders, oncohematological and other pathologies).

          3. Exacerbation or decompensation of chronic diseases affecting the patient's ability to
             participate in a clinical trial.

          4. Oncological diseases.

          5. Medical history of polyvalent allergy.

          6. Allergy / intolerance to any of the components of medications used in the treatment.

          7. Impaired glucose tolerance, diabetes mellitus type 1 and 2.

          8. Hereditary fructose intolerance (due to the presence of maltitol in the examined
             medicine).

          9. Intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot; for 1
             month prior to participation in the trial.

         10. Pregnancy, breast feeding.

         11. Drugs usage, alcohol usage in the amount over 2 units of alcohol per day.

         12. Patients with mental disorders.

         13. Patients, who from investigator's point of view will fail to comply with the
             observation requirements of the trial or with the intake regimen of the investigated
             medicines.

         14. Participation in other clinical trials in the course of 3 months prior to inclusion
             into the present trial.

         15. Other factors, which hinder the patient's participation in the trial (for example,
             planned trips or business trips).

         16. The patient is related to the research personnel of the centre who are directly
             involved in the trial or are the immediate family of the researcher. The immediate
             family includes husband / wife, parents, children or brothers / sisters, regardless
             of whether they are natural or adopted.

         17. The patient works for OOO &quot;NPF &quot;Materia Medica Holding&quot;, i.e. s/he is the company's
             employee, temporary contract worker, and designated official responsible for carrying
             out the research or their immediate family.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74957836804</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Non-governmental Health Care Institution &quot;Road Clinical Hospital at the train station Chelyabinsk of OJSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;Kazan State Medical University&quot;</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rustem Khamitov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Rustem Khamitov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;The Russian National Research Medical University named after N.I. Pirogov&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Bart, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Boris Bart, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;The Russian National Research Medical University named after N.I. Pirogov&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Mikhailusova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marina Mikhailusova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Scientific Research Institute for Vaccines and Serum named after I.I.Mechnikov&quot; of Russian Academy of Medical Science</name>
      <address>
        <city>Moscow</city>
        <zip>105064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Polyclinic № 3&quot; of Affairs Management Department of the President of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Minina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Minina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Panacea Clinic&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>117630</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Municipal Health Care Institution &quot;Podolsk city clinical hospital №3&quot;</name>
      <address>
        <city>Podolsk</city>
        <zip>142105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Regional State Budgetary Health Care Institution &quot;Policlinic № 6&quot;</name>
      <address>
        <city>Smolensk</city>
        <zip>214000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Health Care Institution Policlinic № 1 of the Russian Academy of Sciences</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Сity Polyclinic № 4&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Medical Exercises Dispensary&quot; of Krasnogvardeysky District</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;St. Petersburg State Medical University named after I.P. Pavlov&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Ilkovich, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Mikhail Ilkovich, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;St. Petersburg State Medical University named after I.P. Pavlov&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Сity Polyclinic № 117&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot; Nevsky Region Сity Polyclinic №25&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Voronezh State Medical Academy of N. N. Burdenko&quot; Ministry of Health of the Russian Federation</name>
      <address>
        <city>Voronezh</city>
        <zip>394036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Babkin, MD,PhD, ScD, professor</last_name>
    </contact>
    <investigator>
      <last_name>Andrey Babkin, MD, PhD, ScD, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education &quot;Yaroslavl State Medical Academy&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitriy Petrov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dmitriy Petrov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budgetary Health Care Institution of the Yaroslavl region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Yanovskaya, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Yanovskaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
